Moreover, treatment with AR inhibitor enzalutamide for HER2+ ER− breast cancer decreases HER2 phosphorylation, and treatment with enzalutamide plus trastuzumab further improves the inhibition of cell growth compared to single drug treatment [216]. This evidence concerns the gene ERBB2 and breast carcinoma.